Transplant Capabilities

• Five organ types available at CCAD (kidney, liver, heart, lung, pancreas) with 95% overall success rate; SKMC reports 99% one-year and 98% five-year kidney survival
• Deceased-donor wait times: 3 months (blood type AB) to 3-5 years (blood type O); living-donor programs offer faster access and are the primary medical tourism pathway
• Federal Decree Law No. 25 of 2023 prohibits organ commercialization and provides nationality-neutral legal framework; deceased-donor list requires UAE residency
• Kidney transplant costs ~USD 30,000 (93% savings vs US); liver ~USD 200,000 (30-60% savings vs US/UK)
• Comprehensive international patient services across major centers including visa facilitation, accommodation, multilingual support, and long-term follow-up coordination

Read the full United Arab Emirates report →

• 46-50 JCI-accredited hospitals with transplant programs available, far exceeding 2-3 centers required for Score 4
• Kidney transplant 1-year graft survival of 94% overall and 96% for living donors; liver transplant 1-year survival exceeds 90% (exceeds Score 4/5 thresholds of 85%+ kidney/liver)
• Wait times of 3-4 weeks for international patients with living donors (far better than 6-12 month Score 4 window)
• Cost savings of 50-70% compared to US/UK/Canada, meeting Score 5 criteria
• International patients restricted to living donor transplants only; must bring their own donors; no access to deceased donor organs due to Turkish law

Read the full Turkey report →

• 4 JCI-accredited transplant centers in Amman (Jordan Hospital, Specialty Hospital, PHCUOT, Arab Medical Center)
• Kidney transplant success rates of 91-97% at 1 year, exceeding international benchmarks
• Only 2 organ types available to international patients (kidney and liver); heart program suspended since 2020; lung and pancreas not offered
• Living-donor-only legal requirement (relatives up to fifth degree or spouses); deceased-donor program non-functional with 0.3 per million population donation rate
• Cost savings of 85-90% vs US pricing (USD $15,000-$25,000 for kidney transplant vs USD $150,000-$450,000+ in US)

Read the full Jordan report →

• Heidelberg University Hospital operates dedicated international patient division with 240+ annual transplants (140 kidney, 100 liver) offering visa support, interpreters, and comprehensive treatment services
• Transplant outcomes exceed international benchmarks: kidney 96% one-year graft survival, lung 91-92%, heart 86-88% per DSO and IQTIG data
• Deceased-donor kidney wait times: 5.8-7 years for Eurotransplant-eligible patients; non-EU nationals effectively excluded from deceased-donor waiting lists
• Living-donor pathway shows 2-6 month wait once donor approved, but restricted by Transplantationsgesetz to close relatives or documented personal relationships, limiting international access
• Cost structure: kidney $17,000-$105,000 (vs US $200,000-$250,000) represents 30-50% savings, comparable to Western European destinations but not competitive with lower-income countries

Read the full Germany report →

• 3-4 JCI-accredited transplant centers (Clínica Universidad de Navarra, Hospital Clínic Barcelona/barnaclínic+, Fundació Puigvert, Hospital Ruber Internacional) actively accepting international patients
• Categorical exclusion of non-residents from deceased-donor waiting list per two-year residency requirement since 2018; non-residents limited exclusively to living-donor programs
• Outcomes substantially exceed international benchmarks: kidney 97-99% at 1 year, liver 90-99% at 1 year, heart 85.2% at 1 year
• Kidney transplant costs €70,000-€100,000 providing 60-75% savings versus US pricing of $250,000-$400,000
• Comprehensive post-transplant care coordination at leading centers; Clínica Universidad de Navarra maintains dedicated international patient team for 110+ countries
• Only 2-3 organ types accessible to international patients (living-donor kidney, living-donor liver partial, limited heart valve); full heart and lung transplants inaccessible
• No explicit documentation of annual international transplant volume; Barnaclínic+ performs ~50 living-donor kidney transplants annually but international proportion unclear

Read the full Spain report →

• 5 JCI-accredited transplant centers (NUH/NUCOT, SGH, NHCS, Mount Elizabeth, Gleneagles) with global recognition
• Living-donor kidney: 90% 10-year graft survival (exceeds US 82.7%) and SGH achieved 100% 1-year patient/graft survival (2022-2023)
• Living-donor liver: SGH reported 100% 1-year patient and graft survival since 2015 with zero living-donor mortality
• Kidney transplant costs USD 50,999-85,999 vs USD 300,000-400,000 in US; liver USD 148,000-275,000 vs USD 500,000+ in US
• Clear ethical legal framework: HOTA/MTERA with mandatory Transplant Ethics Committee approval, 7-day mandatory cooling-off period, WHO compliance, absolute prohibition on organ trading
• Only 2 organ types realistically available to foreigners (living-donor kidney/liver); deceased-donor organs and hearts/lungs essentially inaccessible due to 9-year kidney wait, only 1 heart and 0 lungs performed nationally in 2024

Read the full Singapore report →

• Rabin Medical Center performs all five solid organ types (kidney, liver, heart, lung, pancreas) with cumulative experience of 2,500+ kidney, 500+ liver, 400+ lung, 100+ heart, and 50+ pancreas transplants, but deceased-donor organs are legally prohibited to non-residents
• Multiple JCI-accredited centers (Sheba since 2013, Rabin, Sourasky, Hadassah) available for living-donor cases, exceeding the '1-2 centers' threshold of Score 3 on infrastructure alone
• Kidney living-donor survival rates of 95% at 1 year and liver survival of 85-90% substantially exceed international benchmarks and Score 3 expectations
• Cost savings of 50-70% for kidney transplants ($80,000-142,000 vs. US ~$442,500) exceed all score levels except 5, but limited to living-donor cases for foreigners
• Non-residents legally barred from deceased-donor organs per 2008 Organ Transplant Law; foreign nationals eligible only for living-donor transplants from first-degree relatives with Ministry of Health Special Committee approval, fundamentally restricting organ types available to international patients

Read the full Israel report →

• Only 3-4 private transplant centers accept international patients, limited to living-donor kidney and liver pathways
• Deceased-donor organs explicitly restricted to NHS-eligible (UK-resident) patients by law and policy; no access for foreigners to most organ types
• Survival rates are world-class where accessible: 99% one-year patient survival for living-donor kidney, 88.5% for liver, >95% for heart
• No cost savings: kidney transplant costs £40,000-55,000, comparable to Germany/France and 2-4x higher than India/Turkey
• Report concludes: 'The United Kingdom is not a primary organ transplant destination for medical tourists'

Read the full United Kingdom report →

• Only ~30 foreign nationals on waiting list in 2022, overwhelmingly Ukrainian residents, not elective medical tourists
• Average kidney transplant wait time 430 days (up to 12 years for longest-waiting), far exceeding medical tourism feasibility
• No JCI or international accreditation for transplant programs; no fast-track or premium programs for foreign patients
• Living-donor kidney transplants at only 0.8 per million population—among Europe's lowest; paired-kidney exchange program nascent
• Poland not a member of Eurotransplant and organ transplants explicitly excluded from EU cross-border healthcare reimbursement
• Multiple high-volume centers (Warsaw UCC MUW, Silesian Centre) with good transplant outcomes (kidney 95% 1-year, liver 84%, heart ~75%) and institutional experience
• Clear ethical framework and no documented organ trafficking; cost savings 40–70% below Western Europe; 22% annual growth in transplant volumes
• No published pricing, all-inclusive packages, or dedicated international patient coordinators; country ranked 29th of 46 in Medical Tourism Index and not listed among transplant tourism destinations

Read the full Poland report →

• Deceased donor kidney wait time: 13-15 years with only 82 cadaveric donations utilized in all of 2024; deceased donor organs allocated to domestic patients only
• Liver transplant one-year survival: 73.9% (below international benchmark of 85-90%)
• Very limited surgical capacity: only 2 transplant surgeons in public system; no formal transplant surgery training program
• Malaysia explicitly not a primary transplant tourism destination; no evidence of serving 100+ international patients annually
• JCI-accredited centers (IJN since 2009, Gleneagles KL, SJMC) with international patient services and cost savings of 65-93% versus US

Read the full Malaysia report →

• Only 1 JCI-accredited transplant center (Fujita) with explicit international patient program; Fujita performs 500+ total transplants but publishes no international volumes
• Deceased-donor kidney wait times 13–18.7 years (versus Score 2 threshold of 24+ months); living-donor kidney transplants constitute 85% of volume but are restricted to blood relatives, eliminating primary access pathway for medical tourists
• Excellent transplant outcomes across all organs (heart 10-year 93.5%, kidney living-donor 5-year >96%, liver 5-year 85–95%, pancreas 1-year 95.8%) but world-class quality is irrelevant if inaccessible
• Active Declaration of Istanbul commitment and institutional anti-transplant-tourism stance create de facto barriers despite no formal legal prohibition on foreign patients
• Estimated uninsured kidney transplant cost ~USD 100,000–167,000 year-one (comparable to Western prices), with no published international pricing structure or cost advantage

Read the full Japan report →

• Non-resident foreign patients explicitly excluded from transplant waiting list by Act CLIV of 1997
• EU Cross-Border Healthcare Directive (2011/24/EU) explicitly excludes organ transplants from coverage
• Zero documented international transplant patients; 411 total transplants in 2025 all domestic/Eurotransplant exchange
• No published pricing for foreign patients; system is public university hospital-based with no commercial infrastructure
• Semmelweis University ranked 1st among 77 Eurotransplant centers for kidney transplants and 2nd in Europe for heart, indicating elite technical quality incompatible with accessibility restrictions
• Living-donor transplant theoretical pathway exists but no documented protocol for foreign patients; would require case-by-case institutional approval

Read the full Hungary report →

• Only ~0.4% of US transplants (~40 annually) go to foreign nationals traveling specifically for transplantation, with 1.4% overall to non-US residents
• Deceased donor wait times average 3-5 years for kidneys, 1-5 years for livers—far exceeding the 24-month threshold and making deceased donor access impractical for medical tourists
• Kidney transplant costs average $446,800 billed charges; heart transplants ~$1.9M—the highest in the world and 7-30× more expensive than leading medical tourism competitors
• January 2026 House Ways and Means Committee investigation into University of Chicago Medical Center and Montefiore Medical Center for allegedly providing disproportionately fast organ access to wealthy foreign nationals raises concerns about ethical practices
• While 1-year kidney survival (97.4%), liver survival (85-90%), and heart survival (~95%) are world-class, these exceptional outcomes do not overcome fundamental unsuitability for medical tourism due to cost, wait time, and access barriers

Read the full United States report →

• Law 1805 of 2016 and Constitutional Court ruling C-372-19 explicitly prohibit organ transplantation for non-resident foreigners except through living-related donor cases with dual-country government authorization
• Only 5-10 foreign patients transplanted annually (vs 100+ for score 4, 200+ for score 5)
• Non-resident foreigners legally barred from national organ waiting list; no access to deceased-donor organs
• Multiple JCI-accredited transplant centers (Valle de Lili, HIC, Fundación Santa Fe, Hospital Pablo Tobón Uribe) spanning 6 organ types
• Exceptional kidney transplant outcomes of 97.2% at 1 year and liver transplants of 82-90%, with cost savings of 50-70% below US/European levels

Read the full Colombia report →

• Federal Law 9,434/1997 prohibits organ allocation to non-resident aliens, barring access to deceased donor organs
• Living donor transplants restricted to biological relatives up to 4th degree or spouses; unrelated donors require judicial authorization
• 127 kidney, 59 heart, and 14 lung transplant centers exist but functionally closed to most international patients
• Living donor kidney survival rates excellent at 94% (1-year), 86% (5-year); heart transplant outcomes below international benchmarks at 68.1% (1-year)
• Altruistic donor chains and paired kidney exchanges explicitly forbidden
• No clear evidence of 100+ annual international transplant patients
• Multiple JCI-accredited private hospitals (Hospital Israelita Albert Einstein, Hospital Sírio-Libanês) maintain international patient divisions but capacity remains severely restricted by law

Read the full Brazil report →

• Mandatory 6-month residency requirement for foreign patients prior to transplant eligibility
• 8 JCI-accredited hospitals with transplant programs serving Mexico City, Cancun, Tijuana and other major cities
• Excellent survival rates: 94% at 1 year for liver transplants at leading center, 97.2% patient survival and 95.5% graft survival for kidney transplants
• Significant cost savings: kidney transplants $22-35K vs US prices, liver transplants $70-150K vs $575-875K in US
• Report concludes residency requirement 'effectively eliminates Mexico as a viable option for most international patients seeking immediate transplantation'

Read the full Mexico report →